Abiopharma

🔍 Chen Katy (Executive)

Company: KIMBERLY CLARK CORP (KMB)

Report Date: 2026-04-26

Detailed Transactions and Holdings:

• Acquired 3,087 shares of Common Stock (Direct)
  Date: 2026-04-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,084.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 823 shares of Common Stock (Direct)
  Date: 2026-04-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,907.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 823 shares of Restricted Share Units 4/26/2023 (w/dividends reinvested) (Derivative)
  Date: 2026-04-26 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2, F3, F4, F4

Footnotes:

• F1: Represents performance-based restricted share units that have vested and are paid out in shares of common stock and includes restricted share units which were accrued based on dividends paid on the Corporation's common stock.
• F2: Represents restricted share units that have vested and are paid out in shares of common stock. Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock.
• F3: Represents restricted share units, payable on a 1-for-1 basis. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock.
• F4: The restricted share units vest 30 percent on each of the first and second anniversaries of the grant date and the remaining 40 percent on the third anniversary of the grant date.